Bluebird bio to sell sickle cell FDA voucher for $103 mln if therapy approved

The voucher, which is transferable, allows a drug developer to expedite the review process of its product even if it does not fit requirements for a quick process. This would be the third priority voucher sale for bluebird after selling two for a combined $197 million over the past one year.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/cOqEaMV
via